Search Results

Your search for Katarzyna J. Jerzak, MD, FRCPC, and Kathleen I. Pritchard, MD, FRCPC,Katarzyna J. Jerzak, MD, FRCPC, and Kathleen I. Pritchard, MD, FRCPC matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / July 25, 2016

Revisiting Ovarian Ablation in Early Breast Cancer: A Mismatch Between Global Values and Clinical Practice Guidelines

ASCO recently released a clinical practice guideline update on ovarian suppression as part of the extant guideline on adjuvant endocrine therapy in hormone receptor–positive breast cancer, and the recommendations were summarized in the June 10, 2016, issue of The ASCO Post. Also in this issue,...

breast cancer

By Katarzyna J. Jerzak, MD, FRCPC, and Kathleen I. Pritchard, MD, FRCPC / June 10, 2016

Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer

Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...

Dec

Today In Oncology

Search Results

Your search for Katarzyna J. Jerzak, MD, FRCPC, and Kathleen I. Pritchard, MD, FRCPC,Katarzyna J. Jerzak, MD, FRCPC, and Kathleen I. Pritchard, MD, FRCPC matches 2 pages

Revisiting Ovarian Ablation in Early Breast Cancer: A Mismatch Between Global Values and Clinical Practice Guidelines

Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer

Ramucirumab Paclitaxel as Switch Maintenance in Advanced HER2-Negative Gastric Gastroesophageal Junction Cancer

Evidence-Based Recommendations and Knowledge Gaps Regarding Cardio-Oncology

Pharmacokinetic Comparison of Aumolertinib Osimertinib Gefitinib and Their Major Metabolites in NSCLC

MRD-Guided Chemotherapy Intensification After Induction in Fit Older Patients With AML

Study May Illuminate Cause of Common Checkpoint Inhibitor Adverse Effect